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INTRODUCTION 
 
Most effective interventions for acute stroke are time limited so that treatment has to 
be commenced within 4.5 hours (intravenous alteplase) or 6 hours (mechanical 
thrombectomy) of ictus (1-3). Within these time windows, efficacy is time-dependent 
with the greatest benefit occurring when treatment starts very early after stroke onset 
(2, 3). These interventions are only appropriate for ischaemic stroke and require prior 
brain scanning to exclude intracerebral haemorrhage. Further, they are both 
expensive. There are no definitive treatments for patients with spontaneous 
intracerebral haemorrhage (ICH) although intensive blood pressure (BP) lowering in 
the hyperacute period may be effective, as is recommended in guidelines (4-6). 
One approach to accelerating the onset of treatment is to deliver interventions before 
hospital admission with recruitment at the emergency scene or in the ambulance. 
Several pilot trials have assessed a variety of interventions including magnesium, 
insulin, remote ischaemic conditioning, and BP lowering (7-15). A common feature of 
these treatments is that prior brain imaging is not required, although successful 
studies of mounting a CT scanner and point of care laboratory in an ambulance have 
also been performed in patients with suspected stroke (16). Recently, the FAST-Mag 
trial showed that it was feasible to deliver a large phase III trial in the pre-hospital 
arena, at least in the US emergency care system and with medical support and 
consent via telephone (17). 
 
Nitric oxide donors 
In view of their multi-modal effects, nitric oxide (NO) donors are candidate treatments 
for acute stroke (18, 19). NO is a mixed arterial and venous vasodilator, modulates 
vascular and neuronal function, and inhibits apoptosis. As such, it is a key 
neurovascular modulator and yet circulating levels are low in acute stroke (20). 
Preclinical stroke studies have shown that supplementation of NO with donors reduce 
stroke lesion size if given very early in a variety of stroke models, and improves 
regional cerebral blood flow in permanent models of stroke (21). Four small clinical 
studies of glyceryl trinitrate (GTN), a NO donor that can be administered 
transdermally, in patients with recent stroke found that it reduced blood pressure (an 
independent risk factor for a poor outcome (22-24)) and pulse pressure; had no 
effects on middle cerebral artery blood flow velocity, cerebral blood flow, or 
intracranial pressure; did not alter platelet activity (so GTN can be given in ICH); 
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improved vascular compliance; and had no apparent safety concerns (14, 25-27). In 
the last of these pilot studies (Rapid Intervention with Glyceryl trinitrate in 
Hypertensive stroke Trial (RIGHT)), GTN was administered by paramedics in the 
ambulance within 4 hours of stroke onset and significantly improved functional 
outcome (14). The large Efficacy of Nitric Oxide in Stroke (ENOS) trial (4,011 patients 
recruited from 173 sites in 23 countries) found that GTN was safe to administer but 
did not modify outcome if given within 48 hours of stroke onset (28); however, 
functional outcome was improved in those patients recruited within 6 hours (a pre-
specified subgroup) (28, 29), this result mirroring that seen in RIGHT (30). 
 
Rapid Intervention with Glyceryl trinitrate in Hypertensive strokeTrial-2 
(RIGHT-2) trial 
On the basis of pre-clinical data for NO donors, and clinical data showing feasibility, 
tolerability and safety of GTN, and the potential for efficacy if given very early after 
stroke, the RIGHT-2 trial is assessing the safety and efficacy of GTN when 
administered by paramedics in the pre-hospital environment to 850 patients from 
across the UK, as detailed in the trial’s published protocol (31). The primary outcome 
and analysis is a comparison of the modified Rankin Scale between treatment groups 
assessed using ordinal logistic regression. The present paper details the statistical 
analysis plan (SAP), as given in the accompanying supplement. This information is 
presented blinded to treatment assignment and prior to locking of the trial database 
so that analyses are not data-driven or selectively reported (32). Following on from 
the ENOS trial and its protocol (33), this SAP includes not just information on the 
primary publication (GTN vs no GTN) but also describes information on additional 
planned publications, including baseline characteristics, and a series of secondary 
publications. 
 
Data sharing 
Once completed, data from RIGHT-2 will be added to summary and individual patient 
data (IPD) meta-analyses in acute stroke, first those focusing on nitric oxide donors 
(30, 34), and then of blood pressure lowering (through the ‘Blood pressure in Acute 
Stroke Collaboration’, BASC) (35, 36). IPD will be made available to the ‘Virtual 
International Stroke Trials Archive’ (VISTA) (37), and subsequently over the web, as 
with the International Stroke Trial (38). Similarly, anonymised baseline and on-
treatment neuroimaging data will be published (39). 
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Supporting information 
Additional supporting information may be found in the online version of this article 
with the accompanying Supplement (RIGHT-2 SAP Supplement). 
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